Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2025-07-02 00:00:00 ET · period of report 2025-07-01 · accession 0001735276-25-000077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-02 | 2025-07-01 | ALNY | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | A - Grant | $0.00 | +7,763 | 21.3K | +57% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-01 | A | A | 7,763 | $0.00 | 21,264 | D | — | — | (F1) These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. |